Who
Mollie Leoni
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Kura Oncology.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $3.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jan 2025
- Last trade
- 29 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Jan 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $310K28,802 at $10.75 | filing |
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $310K28,802 at $10.75 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $131K12,448 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $131K12,448 at $10.50 | filing |
| 18 Jun 2026filed 22 Jun 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $834K84,929 at $9.82 | filing |
| 18 Jun 2026filed 22 Jun 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $834K84,929 at $9.82 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $31K3,655 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,233 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $8,046951 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $11K1,341 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $31K3,655 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $19K2,233 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $8,045951 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $11K1,341 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $173K15,485 at $11.18 | filing |
| 13 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —82,500 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Mollie Leoni; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.